Achieve Life Sciences announced data from the Phase 2 ORCA-V1 vaping cessation trial will be presented today, Friday, May 17, 2024, at the Society of General Internal Medicine, SGIM, Annual Meeting being held in Boston, MA. Dr. Nancy Rigotti, ORCA-V1 Principal Investigator and Professor of Medicine at Harvard Medical School, and Director of the Tobacco Research and Treatment Center at Massachusetts General Hospital, will present data from the Phase 2 ORCA-V1 trial. This study explored the efficacy and safety of cytisinicline in adult smokers seeking to quit nicotine e-cigarettes. In the study, treatment with cytisinicline more than doubled the likelihood of quitting compared to placebo.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
- Achieve Life Sciences price target lowered to $11 from $18 at Oppenheimer
- Achieve Life Sciences reports Q1 EPS (26c), consensus (24c)
- Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
- ACHV Earnings this Week: How Will it Perform?